Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • OP 7.3 – 00139 Pre-treatment I...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
OP 7.3 – 00139 Pre-treatment Interruption Plasma Metabolites and Glycans Correlate with Time to HIV Rebound and Reservoir Size in ACTG A5345

OP 7.3 – 00139 Pre-treatment Interruption Plasma Metabolites and Glycans Correlate with Time to HIV Rebound and Reservoir Size in ACTG A5345

Bibliographic Details
Main Authors: L.B. Giron, X. Yin, S.G. Deeks, R.T. Gandhi, A. Landay, Q. Liu, B.J. Macatangay, D.M. Smith, J.Z. Li, M. Abdel-Mohsen
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Journal of Virus Eradication
Online Access:http://www.sciencedirect.com/science/article/pii/S2055664022001996
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S2055664022001996

Similar Items

  • Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)
    by: Aga Evgenia, et al.
    Published: (2010-08-01)
  • Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption
    by: Leila B. Giron, et al.
    Published: (2021-02-01)
  • Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.
    by: Jean-Jacques Parienti, et al.
    Published: (2008-07-01)
  • Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption
    by: You Park, et al.
    Published: (2017-11-01)
  • Extreme Phenotypic Variability of ACTG1‐Related Disorders in Hearing Loss
    by: Maria T. Bernardi, et al.
    Published: (2024-12-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs